Latest News Story Headlines
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneurophathy (ATTRv-PN) through 66 weeks
Published 27 March 2023
2023 Winter Newsletter
Be sure to catch up on the latest happenings in our winter newsletter here!
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022
November 5, 2022
Calendar & Upcoming Events
Support Group Meeting - New York
The Weill Cornell Medicine Center holds free amyloidosis support group meetings virtually every month. These groups are led by a medical oncology
Sign Up for the Latest Updates
Get news from Amyloidosis Foundation
in your inbox
By submitting this form, you are consenting to receive marketing emails from : Amyloidosis Foundation, 7151 N. Main St., Suite 2, Clarkston, MI, 48346, US, https://www.amyloidosis.org. You can revoke your consent to receive emails at any time by using SafeUnsubscribe© link, found at the bottom of every email. Emails are serviced by Constant Contract.